Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Prevention & Management of Medication-Related Osteonecrosis of the Jaw

Pooja Gangwani, DDS, MPH  |  Issue: March 2021  |  March 15, 2021

Medication-related osteonecrosis of the jaw (MRONJ) is a con­dition that manifests as exposed, necrotic and non-healing jaw bone in patients who have been treated with bisphosphonates, denosumab, chemotherapeutic agents, anti-angiogenic drugs, tyrosine kinase inhibitors, thalidomide and steroids.1-4 These medications are admin­istered via intravenous, subcutaneous and oral routes to manage osteopenia; osteoporosis; hypercalcemia of malignancy; bone metastases of tumors including lung, prostate and breast; and the lytic lesions of multiple myeloma.4 

Pathogenesis & Treatment 

In patients with MRONJ, the mandible is twice as likely to be involved as the maxilla.4 Three theories have been proposed relating to the pathogenesis of MRONJ:4-6 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Inhibition of osteoclastic function and increase in osteoclast apoptosis, which negatively affect bone healing and remodeling;
  2. Inflammation and infection secondary to biofilms; and 
  3. Interruption of vascular supply leading to osteonecrosis. 

MRONJ’s four stages, stage 0 to stage 3, reflect disease severity.4 Based on the staging and severity of the condition, MRONJ can be managed surgically and/or non-surgically.4 

The non-surgical therapeutic approach includes pain control, antibacterial mouth rinses, systemic antibiotics, pentoxifylline and alpha-tocopherol. Surgical treatment includes debridement and sequestrectomy, resection and reconstruction.7 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Risk Factors 

Dentoalveolar surgery increases the risk of MRONJ, with tooth extraction being the most common precipitating factor.4 In a study conducted by Saad et al., tooth extraction as a predisposing event was reported by 61% of patients with MRONJ.8 Similarly, Hoff et al. identified dental extraction as a risk factor in 55% of patients in their cohort who developed MRONJ.9 

The above-mentioned studies included patients treated with intravenous and subcutaneous bisphosphonates. 

Hasegawa et al., in their multicenter, retro­spective study, documented the incidence of post-extraction MRONJ in patients who received oral bisphosphonates as 1.7%.10 

The best current estimate for the risk of developing MRONJ in patients on oral bisphosphonates after tooth extraction is 0.5%, whereas the risk for patients with cancer exposed to intravenous bisphosphonates ranges from 1.6–14.8%.4 

A study conducted by Yamazaki et al. on patients receiving oral bisphosphonates for more than three years has demonstrated delayed recovery, with persistent bone exposure in the extraction sockets at four weeks, suggesting delayed epithelialization may be a cause of MRONJ.11 

Bisphosphonates & Delayed Wound Healing

Several researchers have investigated the complex relationship between bisphosphonates and oral tissue toxicity. The results of these studies have revealed decreased oral epithelial cell migration and apoptosis, further causing delayed oral mucosal wound healing.12 

In 2008, Landesberg et al. studied the effects of pamidronate on oral mucosal cells in a murine model. They found oral epithelial proliferation and wound healing were inhibited at pamidronate concentrations above 0.1 mmol/L, thereby contributing to the development of MRONJ through persistent exposure of the underlying bone.13 

Scheper et al. assessed the apoptotic effects of zoledronic acid on human gingival fibroblast and keratinocyte cell lines using an in vitro model. They concluded that the direct contact of clinically relevant concentrations of zoledronic acid causes apoptosis of epithelial and fibroblast cells.14 

Cell death and suppression of epithelial proliferation ultimately leads to mucosal thinning and breakdown, causing bone exposure and rapid microbial colonization, resulting in MRONJ.5,14 Therefore, it can be concluded that epithelialization and mucosal healing is an essential step in the management of MRONJ.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Conditions Tagged with:bisphosphonatesbone mineral density (BMD)Osteonecrosis

Related Articles

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    October 13, 2015

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

    Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw

    December 12, 2022

    A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.

    Reporting & Other Tips for the CARES Act Provider Relief Fund

    February 16, 2021

    Between April and December 2020, many eligible healthcare providers received or applied for payments from the $175 billion Coronavirus Aid, Relief and Economic Security (CARES) Act Provider Relief Fund (PRF) through the U.S. Department of Health & Human Services (HHS). On Dec.27, 2020, the Consolidated Appropriations Act, 2021 (the Appropriations Act) was signed into law,…

    Reading Rheum

    May 1, 2009

    Handpicked Reviews of Contemporary Literature

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences